Brussels / Nantes, December 21, 2007 - Eurofins is very pleased to announce the promotion of Michael Russell to President of the US Food Division effective January 1, 2008. Mr. Russell will lead the Eurofins US Food Operations which currently consists of Eurofins Scientific, Inc., Eurofins Genescan, Inc., and Eurofins Central Analytical Laboratories, Inc. This appointment is made in conjunction with an increased strategic commitment by Eurofins to expand its presence in the North American market through organic growth at each of its current locations but also through strategic acquisitions.
Since 1998, Mr. Russell served as the President of Eurofins Genescan, Inc. in New Orleans, Louisiana, the global leader in the field of GMO detection. In this role, he has been responsible for the business development and operations management of Eurofins GeneScan, Inc. since its inception. He will now be based in the US Corporate Headquarters located in Des Moines, Iowa. Dr. Frank Spiegelhalter, Executive Vice-President of Eurofins GeneScan, Inc. will assume the operational leadership for the New Orleans-based subsidiary.
Eurofins – a global leader in bio-analysis
Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors. With over 7,000 staff in more than 100 laboratories across 27 countries, Eurofins offers a portfolio of over 25,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by our highly qualified staff.
The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both, its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international player in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the demands of regulatory authorities around the world. The shares of Eurofins Scientific are listed on Euronext in the Paris (ISIN FR0000038259) and Frankfurt (WKN 910251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The
forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forwardlooking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.